Evaluating treatment strategies in chronic lymphocytic leukemia: Use of quality-adjusted survival analysis

Journal of Clinical Epidemiology

Volumn 54, Issue 7, 2001, Pages 747-754

  Levy, Vincent ^a,b   Porcher, Raphaël ^a,b   Delabarre, Fabrice ^a   Leporrier, Michel ^c   Cazin, Bruno ^d   Chevret, Sylvie ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Chronic lymphocytic leukemia; Q TWIST; Quality of life; Treatment*

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISONE; VINCRISTINE SULFATE;

ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOXICITY; EVALUATION; HUMAN; MAJOR CLINICAL STUDY; NEUROTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; PREDNISONE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIDARABINE; VINCRISTINE;

EID: 0034957558     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(00)00359-0     Document Type: Article

References (32)

1. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia
2. Chronic lymphocytic leukemia
3. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia
4. Chemotherapeutic options in chronic lymphocytic leukemia; a meta-analysis of the randomized trials
5. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL
6. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy
7. First line fludarabine treatment of symptomatic chronic lymphoproliferative diseases; clinical results and molecular analysis of minimal residual disease
8. Absence of minimal residual disease detectable by FACS, Southern blot or PCR in patients with chronic lymphocytic leukaemia treated with fludarabine
9. Randomized comparison of fludarabine, CAP and ChOP in 695 previously untreated stage B and C chronic lymphocytic leukemia (CLL). Early stopping of the CAP accrual
10. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer
11. Costs and benefits of adjuvant therapy in breast cancer; a quality-adjusted survival analysis
12. Quality adjusted survival analysis
13. The duration of a life of quality should become the focus of 'quality-of-life' studies
14. Comparing treatments using quality-adjusted survival; the Q-TWiST method
15. A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. International Breast Cancer Study Group
16. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer
17. Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma; an aid to clinical decision making
18. Quality-of-life-adjusted survival for comparing cancer treatments. A commentary on TWiST and Q-TWiST
19. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection
20. Measuring patient-centered outcomes in neurologic disease. Extending the Q-TWiST method
21. The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis
22. Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma
23. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma; up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial
24. Quality-adjusted survival after treatment for acute myeloid leukemia in childhood; a Q-TWiST analysis of the pediatric oncology group study 8821
25. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis
26. Nonparametric estimation from incomplete observations
27. Chronic lymphocytic leukaemia
28. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia; revised guidelines for diagnosis and treatment
29. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute; five-year follow-up report
30. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma; an Eastern Cooperative Oncology Group study